Clinical trials: Fibrosis Lung
Covid19, Cystic Fibrosis
COVID-19 Antibody Responses In Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT04863573)
- Where
- 11 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Queen's University, Belfast
Cystic Fibrosis
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
The purpose of this study is to assess the pharmacokinetics and safety of VX-809 and VX-770 alone and in combination in healthy subjects.
- Trial name
- NCT01216046
- Testing
- VX-809, VX-770
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Fibrosis
SVF for Treating Pulmonary Fibrosis Post COVID-19
General description of the study This is a prospective, multicenter, expanded access interventional study of subjects recovered from COVID-19 pneumonia to assess their response to intravenous administration of adipose-derived…
- Trial name
- SVFCOVID-19 (NCT06304623)
- Testing
- Autologous adipose-derived SVF IV administration
- Where
- 2 sites in Nicaragua
- Volunteers
- 40 people
- Sponsor
- Michael H Carstens
Cystic Fibrosis
A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor
The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet (FDC) of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA).
- Trial name
- NCT05535959
- Testing
- VX-121/TEZ/D-IVA
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Transition From Pediatric to Adult Cystic Fibrosis Care Center
The main objective of register-SAFETIM is to assess the impact of the transition from pediatric to adult cystic fibrosis care center on changes in lung function and nutritional status of patients.
- Trial name
- SAFETIM RNM (NCT02790879)
- Testing
- Transition pediatric - adult
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis
Sleep in Patients With Cystic Fibrosis
The aim of the study is to identify the parameters that are associated with nocturnal hypoventilation in children and adults with cystic fibrosis.
- Trial name
- Sommeil (NCT00804661)
- Testing
- SENTEC device
- Where
- France
- Volunteers
- 76 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis
Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients
Safety, tolerability and pharmacokinetics following single doses
- Trial name
- NCT02265679
- Testing
- BIIL 284 BS, low dose, pediatric patients, BIIL 284 BS, medium dose, pediatric patients, BIIL 284 BS, high dose, pediatric patients
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis.
- Trial name
- GAP (NCT00373841)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Pittsburgh
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
This study is meant to compare the amount of oxygen required for hypoxemia relief between current standard of care (oxygen only) and oxygen with the addition of high flow air for Chronic Obstructive Pulmonary Disease (COPD)…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Pulmonary Fibrosis, Hypoxemia
- Trial name
- NCT04170062
- Testing
- Nasal Delivery of High-Flow Air and Oxygen Therapy, Nasal Delivery of Oxygen Therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Johns Hopkins University
Idiopathic Pulmonary Fibrosis
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
- Trial name
- NCT05954988
- Testing
- LTI-03
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 24 people
- Sponsor
- Rein Therapeutics
Pulmonary Fibrosis
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel…
- Trial name
- NCT05121779
- Testing
- 68Ga-FAPI, 18F-FDG
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Sickle Cell Disease, Chronic Kidney Diseases
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
The purpose of this study is to test the efficacy of a peer support coaching intervention to improve activated chronic illness self-management versus an attention control group in 225 adolescents and young adults with childhood…
- Conditions
- Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer
- Trial name
- PiCASO (NCT03938324)
- Testing
- PiCASO Intervention Group
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Duke University
Metastatic Breast Cancer, Benign Breast Disease
China CellSearch Study
The study is designed to confirm the current indication (below) of the CellSearch® Circulating Tumor Cell Kit in metastatic breast cancer (MBC) patients for use of the kit in China.
- Trial name
- NCT01116869
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Medical, China
Cystic Fibrosis
Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
The purpose of this study is to validate the user interface of TOBI Podhaler by establishing that the product can support safe and effective use for the intended users
- Trial name
- NCT03502070
- Testing
- Tobi Podhaler
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Mylan Inc.
Cystic Fibrosis
Sweat Response, Sweat Composition and Thermoregulatory Response to Exercise in Heat in Adults With Cystic Fibrosis on Modulator Therapy.
Cystic fibrosis (CF) is a common inherited condition in the Caucasian population resulting in poor function and/or production of the CF transmembrane conductance regulator (CFTR) protein.
- Trial name
- Sweat-CF (NCT05896488)
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Portsmouth
Cystic Fibrosis
The EPIC Observational Study
The purpose of this study is to better define risk factors preceding first isolation of Pseudomonas aeruginosa (Pa) from respiratory cultures in cystic fibrosis (CF) lung disease and to better define clinical outcomes associated…
- Trial name
- EPIC OBS (NCT00676169)
- Where
- 54 sites in United States
- Volunteers
- 1,248 people
- Sponsor
- CF Therapeutics Development Network Coordinating Center
Idiopathic Pulmonary Fibrosis
Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a survival median between 2 and 4 years which leads to a profound alteration of the quality of life.
- Trial name
- PALIF (NCT03229343)
- Testing
- Supportive care
- Where
- 11 sites in France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis
PEP and OPEP Devices in Cystic Fibrosis
Cystic fibrosis (CF) is the most common severe autosomal recessive genetic disease in Caucasians. The CFTR (cystic fibrosis transmembrane regulator) gene, which encodes the chloride channel of the epithelial cell membrane, is…
- Trial name
- NCT05801952
- Testing
- Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Cystic Fibrosis, Pseudomonas Aeruginosa
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pulmonary Exacerbation
- Trial name
- NCT00333385
- Testing
- ceftazidime
- Where
- 15 sites in France
- Volunteers
- 120 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Cystic Fibrosis
Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis
Vitamin D insufficiency is common in patients with cystic fibrosis. The investigators study will examine a large dose of vitamin D given to patients who have cystic fibrosis and are admitted to the hospital for a pulmonary…
- Trial name
- NCT00788138
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Emory University